CBLL1 and colorectal carcinoma: Apart from silencing the expression of E3 ligase to repress the catalytic activity, a recent study defined Hakin-1, the first small molecule inhibitor targeting at the E3 ligase Hakai, blocks Hakai-dependent ubiquitination of E-cadherin in CRC cells, presenting promising therapeutic potential against CRC progression [123].